{"id":833185,"date":"2025-04-02T16:12:04","date_gmt":"2025-04-02T20:12:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/"},"modified":"2025-04-02T16:12:04","modified_gmt":"2025-04-02T20:12:04","slug":"compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/","title":{"rendered":"Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, April  02, 2025  (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025.<\/p>\n<p>\n        <strong>Presentation Details <\/strong><br \/>\n        <br \/>Date: Tuesday, April 8, 2025 <br \/>Time: 3:00 PM EDT<br \/>Webcast Link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xz5z2xdb9-miu0VhFqF7f-VcuDHnxgMnXvfb7FtRNDQHAXWrtFreM27m2iQUX_LJybn9xILrVSUJsaB9YOZayuLANGidFpEG2xrD5OoY307hbilglX2_mTOqhDKcUJnJQeV2QKF3fUdQOsja1I_hxt5Z_9FuHM9B3SKQXNiGrHAS1eJ_YqPYtSkSr2De8maaYE1dy51yKab82LXFgiCsLEiNNlBi4ay7poWLmexu735-luSy2urYby3Vl7opxuAmMgLV3TgN7btbQhyfvFT6GNdsxqlGKL98nnFneijky-5Yjy_wVWDVe4z_Fvvo07SCqzgOu0Lfi41CmoFiQlyFXidda8nXcfZubSFalhDvI0rs81I-FQN4xB2a6ahQfuCfHgApw2hzKJ4qpv0NngUOud1tYHrJBfxsdMI5GelMObnk-vkGd5ojG26bVNrOhTiFb5c849Y4hjS7Vkumfls6QWXkdvfp4Vcf1nZwuVYDMwhhkjnBf7hJWOe6p6eOETVNYOwaEY6uDJz1ZMiTW9XuTJRSwAYtTzt1INeYWphL4HMyrWFiZfw3E9L_S_FUQN-174mU5uFAw_c5zhmNRZZnbvt4HrXTOCJWd8d1QbH6eqaqNRRP2Fj4Ua8M7wq0mMAGwpt74gNPuzBC80lwX74Vx7O2eook0uRoZKjpDBPhQGjy5PY5XkADvX2sRfxJWJP4\" rel=\"nofollow\" target=\"_blank\">https:\/\/wsw.com\/webcast\/stifel99\/cmpx\/2119000<\/a><\/p>\n<p>\n        <strong>Virtual\/Replay availability:\u00a0<\/strong>The corporate presentation will be archived for 90 days on Compass\u2019\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n1lEm2urtDA4sp93k6k3CuS2OA0JVeTdpUqI0WhbcNqqhB_NwikZJsbLkDAgsNmDjQteB5ZcC78q2SNk4EJ9Ks1LgeC3DXt1hJWNrsIwXBV7W6TGrMwHj3P9fiI93MDhgZG0EYjBjX8AOnqCDwiiHekzFgUvJcoEhhQ4ktFy66dUJ1GazWGsBTAlWKDj3MXNw6ztbN_QdVadOB5ggzPHcDeIxdwPfVqZuEmOmCEds34RWLrS0Uz0e52UVQN4gXITSHYYTGF2_Fgm5Z6Lbjm3kQ==\" rel=\"nofollow\" target=\"_blank\"><strong>Events<\/strong><\/a>\u00a0page.<\/p>\n<p>\n        <strong>About Compass Therapeutics<\/strong><br \/>\n        <br \/>Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass\u2019s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xz5z2xdb9-miu0VhFqF7f02tdsf6kXCXhOXioH84WvrDmSeuolovS2vR_46rLr7oLKPFnsxlzCaJXjBw9kIROUjrOYX0c2VH23-_Q_La11yus4lAVJjpzMKqnq_w26QugZ_BD5_oKOqZeS5W8NNN-rIrpV_HBql_PifzUa3ZZC1FrSNfaNHdf8N4KmDL51OPXN5i-e2IyOx2SOa9AhV_R2Fl0bgh00nNRwvEiShzncQ1Ruk42LdGBNgR_E75U-eDiBoyHbU963U7qGKwLMg5FC5eWrRQ6h96YwC3yOVikOKeUpVyJt-cvel1BRbkt_AhR6r8lbuU6F_E4DnoJjHTK7T4U6iyxZmPkexaMrSUvQwNnqABm2NWzBsF2ub1KUoQIo5EILQphWOmFMKykFlkTv6qRfUMn7yOpNxBdEh_QHvTge7CsbTInCgIOTH7DxBgvRf2hHohF4pE4ELKq1uRW2WVLwL5P43o2m52NUgPZOu_tckObOqZ-kSesQcWJ_hH1jKIQ2wWNzIacXItUMeIrSQ6-RxTAi5DXlE1By7f8Rs4kOFrH8978Vz2G8SECoJdIKaRCFc-wuaFGb-oDyNDovyY2nOE3WrNaLgaZLqPUBGj7imxVlSCdSuMd-PwNaPxc7A5upsCspYqFsIfLDPNI-Iab_QYz2flvv76YdslQPnqpeAFT2DhBpon1XFZQ7m8EKB34AVjPwl_pWyiLp8GcH1u4bRfulwzWT8BatCGm8JlaSjp24Oi2NmRHr9hZyhea6yTxAI2ybXA4IJrDJlsiJtiHaYOAsb_zF1SkiRKeo81CIk_a7BVXsarf-PT1HIlbFCOQmK8HASf5sTP4PGvVzgwoIannVTnW8cVV-__7T9efhIs24Hau2fprwPY6xdqWLiJk_iv0C3-PJBnCnuHbRKMYzPxYMd4o89F65JnJCNiX4J6sCrV8dwrsTCumTSW7XCWk_Jb8rCbraSYyAil7yKAdZBE8T74yH8HfV16tE0Gtts7qbTMPzeKg7cc0aw9c0JF4QoMRwbO2r5sgvNHulDQx0ZvBr_39rnX8GuWt2E=\" rel=\"nofollow\" target=\"_blank\"><strong>https:\/\/www.compasstherapeutics.com<\/strong><\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SDYQMHXA-hz2Gu3uK66Qi9wVEKkGv5U73NnN0bH3xncDcKzzoVqGfbcqS0LOFWDNqQK95rZDZUNqdfHVPKy79Yxs_4xj-aD4vWaapqYryr4UXrpsGGm3MMCDxqDdu5-aA5l4TR_YydB0291whCxzN_fEjeNJPM88u-G68i4hKHD7BOi8hFbrG2BIecIaEdbIMuGgxJIZe2O1h2vJHk4OQkXn_TjjV6YwzfmoWBe3yoQ_kFj1pdc4zj8MNo_ljpU-nfnK8O6LG1vC7Q0N1lHxuhvHHynn-K2PylW2uk1X-oY=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>ir@compasstherapeutics.com<\/strong><br \/>\n        <\/a><br \/>\n        <br \/>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Anna Gifford, Chief of Staff<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4BnlmqtHgrXCag1f75bb6rJVBU2GabFpkO-9nGn_t1D_lwue2lJ1Eo22o53h2oANfjXzCE4VAWHRUhItzTRCuJxqhvWMWAL68cv-YZxhILt2dQSzKPJoTj3Drx174CrU8Qywr-BHLveUCaBYsgKTebfScJTY0-aXnTIr0H-6OsfQPkIP_5t45n_5W8OJnkaVP2YA5chF5xA3-PuEELN1zQX4cM5rlzIPe0H7sK1zfTk36du7A2DdZYs4OCvUj5ln9K9LWkzvWAZlSLJgScyC_Nsyy-rpwFx4C-vy5T5LWgClB8aAkUTznwiXUpGz8h7D\" rel=\"nofollow\" target=\"_blank\"><strong>media@compasstherapeutics.com<\/strong><\/a><br \/>617-500-8099<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTkyOSM2ODQ4MjcyIzIyMDI0MjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWRiMzI2MzUtZTBkMC00MGRmLWJkNzgtMDliNTc1MmIwZWFjLTEyMTM5NzUtMjAyNS0wNC0wMi1lbg==\/tiny\/Compass-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, April 02, 2025 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025. Presentation Details Date: Tuesday, April 8, 2025 Time: 3:00 PM EDTWebcast Link: https:\/\/wsw.com\/webcast\/stifel99\/cmpx\/2119000 Virtual\/Replay availability:\u00a0The corporate presentation will be archived for 90 days on Compass\u2019\u00a0Events\u00a0page. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass\u2019s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-833185","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, April 02, 2025 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025. Presentation Details Date: Tuesday, April 8, 2025 Time: 3:00 PM EDTWebcast Link: https:\/\/wsw.com\/webcast\/stifel99\/cmpx\/2119000 Virtual\/Replay availability:\u00a0The corporate presentation will be archived for 90 days on Compass\u2019\u00a0Events\u00a0page. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass\u2019s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical &hellip; Continue reading &quot;Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-02T20:12:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTkyOSM2ODQ4MjcyIzIyMDI0MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum\",\"datePublished\":\"2025-04-02T20:12:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\\\/\"},\"wordCount\":246,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTkyOSM2ODQ4MjcyIzIyMDI0MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\\\/\",\"name\":\"Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTkyOSM2ODQ4MjcyIzIyMDI0MjI=\",\"datePublished\":\"2025-04-02T20:12:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTkyOSM2ODQ4MjcyIzIyMDI0MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTkyOSM2ODQ4MjcyIzIyMDI0MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/","og_locale":"en_US","og_type":"article","og_title":"Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - Market Newsdesk","og_description":"BOSTON, April 02, 2025 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025. Presentation Details Date: Tuesday, April 8, 2025 Time: 3:00 PM EDTWebcast Link: https:\/\/wsw.com\/webcast\/stifel99\/cmpx\/2119000 Virtual\/Replay availability:\u00a0The corporate presentation will be archived for 90 days on Compass\u2019\u00a0Events\u00a0page. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass\u2019s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical &hellip; Continue reading \"Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-02T20:12:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTkyOSM2ODQ4MjcyIzIyMDI0MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum","datePublished":"2025-04-02T20:12:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/"},"wordCount":246,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTkyOSM2ODQ4MjcyIzIyMDI0MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/","name":"Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTkyOSM2ODQ4MjcyIzIyMDI0MjI=","datePublished":"2025-04-02T20:12:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTkyOSM2ODQ4MjcyIzIyMDI0MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTkyOSM2ODQ4MjcyIzIyMDI0MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/833185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=833185"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/833185\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=833185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=833185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=833185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}